Histopathological Results in Patients With Prostate Specific Antigen Below 1.5 ng / ml

Year 2018, Volume: 8 Issue: 3, 207 - 210, 28.09.2018

Eren Altun Gülay Turan Figen Aslan Serpil Paksoy

Abstract

Objectives: Prostate specific antigen (PSA) is the most commonly used marker

for prostate cancer. PSA-based screening has reduced disease-specific mortality.

However, PSA is not specific for prostate cancer, but is specific for prostate tissue and

increases in benign conditions.

Material and Methods: In our study, 63 patients with PSA values of 1.5 ng / ml or less

were evaluated retrospectively with 636 patients who underwent prostate sampling

because of the suspicion of prostate cancer.

Results: In our study, 34.9% prostate cancer and 4.1% ASAP were detected below

1.5 ng / ml of PSA. Our results suggest that a significant number of cancers were

detected below 1.5 ng / ml of PSA.

Conclusion: A significant number of prostate cancers are found below 1.5 ng / ml

PSA. The lack of a PSA value that we can say without prostate cancer leads to the

need for a low cost and reliable marker.

Keywords

Prostate cancer; Prostate Specific Antigen; Prostate Biopsy

References

• Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, et al. Early Stage Prostate Cancer An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. Urology. 2016; 96: 116-120.